Skip to content

The Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Sleep Disorders in Patients Undergoing Video-assisted Thoracoscopic Surgery Lobectomy

The Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Sleep Disorders in Patients Undergoing Video-assisted Thoracoscopic Surgery Lobectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119365
Enrollment
Unknown
Registered
2026-02-26
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative sleep disorders

Interventions

Sponsors

The First Affiliated Hospital of Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Adult patients, aged 18 to 80 years old; 2.The patient is scheduled to undergo thoracoscopic anatomical lung resection under general anesthesia, with the estimated surgery completion time no later than 18:00; 3.ASA levels 1-3; 4.BMI 18.5~28kg/m^2; 5.Voluntarily participate in this study and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Patients with suspected or confirmed OSAS (STOP-BANG score >=3); 2.Restless Legs Syndrome (discomfort in both legs, occurs at rest, relieved by activity, no other neurological symptoms); 3.Chronic insomnia requiring long-term medication or a history of sleep disorders with a preoperative Pittsburgh Sleep Quality Index (PSQI) score above 7; 4.Secondary or multiple thoracic surgeries; 5.Metastatic tumor; 6.Severe organ dysfunction (cerebral infarction, angina pectoris, heart failure, moderate to severe pulmonary function decline, hepatic and renal insufficiency); 7.Ear dermatitis or trauma; 8.Preoperative impaired consciousness, inability to communicate or understand the trial content, or inability to provide informed consent;

Design outcomes

Primary

MeasureTime frame
Incidence of sleep disorders on the second day after surgery;

Secondary

MeasureTime frame
Length of ICU stay;48 hours postoperative salvage analgesia;Postoperative Day 30 Pittsburgh Sleep Quality Index (PSQI) Score;Postoperative Day 30 Pittsburgh Sleep Quality Index (PSQI) Score;Intraoperative opioid dosage (including cumulative intraoperative remifentanil dosage and sufentanil dosage);Postoperative 24h and 48h VAS pain scores at rest and during exercise;Quality of Recovery-15 on the 3rd day after surgery;Postoperative pulmonary complication rate;Postoperative nausea and vomiting incidence;Length of hospital stay;The incidence of sleep disorders 3 days after surgery;Postoperative 48-hour rescue analgesia (opioid consumption, non-opioid analgesic use);Mechanical ventilation time;Intraoperative parameters (operation duration, anesthesia duration, blood loss, urine output);Preoperative and postoperative blood test results: complete blood count, biochemistry (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelet-to-white blood cell ratio (PWR;Perioperative sleep aid medication usage;Postoperative days 1-3 delirium assessment (CAM-ICU);Postoperative anxiety and depression scores (HADS) on days 1 and 3;

Countries

China

Contacts

Public ContactWang Jiafeng

The First Affiliated Hospital of Naval Medical University

feng_smmu@hotmail.com+86 21 31161846

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026